Revolution Medicines got FDA approval for a pancreatic cancer drug. The stock moved. Retail traders bought it. They will lose money anyway because they always do.
The drug blocks RAS proteins. You don't know what RAS proteins are. Neither do the people who bought the stock at market open. They saw "FDA approval" and "cancer" and clicked buy like they were ordering a pizza. The pizza costs $40,000 and arrives never.
Pancreatic cancer kills faster than almost any other cancer. It has a five-year survival rate that makes your portfolio performance look optimistic. Revolution Medicines made a once-daily pill that targets multiple forms of the RAS protein. This is actually impressive. The science here is legitimate. The FDA doesn't hand out approvals for pancreatic cancer drugs like participation trophies.
None of this matters for your trade. The approval was announced. The stock already priced it in. Or it didn't. Or it did but then unpriced it. Or the market makers saw you coming and adjusted the spread just enough to guarantee you buy at the top and sell at the bottom. You think you're investing in cancer research. You're not. You're funding a yacht.
The drug works by blocking proteins that drive tumor growth. Brilliant. Groundbreaking. Could save lives. Your calls expire worthless on Friday. You'll post about it on Reddit. Someone will tell you that you should have bought puts. You'll reply that you're holding long-term now. You're not. You'll panic sell on Thursday.
Revolution Medicines spent years developing this. Researchers worked late nights. Clinical trials took forever. The FDA reviewed mountains of data. And you looked at a chart for eleven seconds and decided this was your moment.
Photo by on Unsplash
Leave a Comment